BMS-986322 for Psoriasis

Recruiting in Palo Alto (17 mi)

+72 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Bristol-Myers Squibb

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called BMS-986322 to see if it can help people with moderate-to-severe psoriasis by reducing inflammation and slowing down skin cell growth.

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for adults who've had plaque psoriasis for at least 6 months, with a moderate to severe level of disease. They should be eligible for phototherapy or systemic therapy and have plaques covering 10% or more of their body. People with certain other immune conditions, significant illnesses, or non-plaque forms of psoriasis cannot join.

Inclusion Criteria

My psoriasis covers 10% or more of my body.

My doctor thinks I am a good candidate for light or systemic therapy.

My BMI is between 18 and 40, and I weigh more than 50 kg (110 lbs).

Exclusion Criteria

I have a serious long-term or recent illness.

I am currently on immune-suppressing medication for a condition like uveitis, IBD, or related to PsO.

Other protocol-defined inclusion/exclusion criteria apply

Treatment Details

Interventions

• BMS-986322 (Monoclonal Antibodies)

Trial Overview The study tests the effectiveness and safety of BMS-986322 compared to a placebo in treating moderate-to-severe psoriasis. Participants will randomly receive either the actual drug or a placebo without knowing which one they are getting.

Participant Groups

Group I: BMS-986322 Dose 3 Experimental Treatment 1 Intervention

Group II: BMS-986322 Dose 2 Experimental Treatment 1 Intervention

Group III: BMS-986322 Dose 1 Experimental Treatment 1 Intervention

Group IV: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania